Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 14,147 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Control Clear all
Completed Phase 2 Interventional

GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

NCT03815825
View directory record Official record
Conditions
Macular Degeneration, Geographic Atrophy
Interventions
IONIS-FB-LRx, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
55
States / cities
Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Nov 9, 2026, 10:30 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families

NCT00723476
View directory record Official record
Conditions
HIV Infections
Interventions
Family Centered Advanced Care Planning (FCACP) sessions, Health education control sessions
Behavioral
Lead sponsor
Maureen Lyon
Other
Eligibility
12 Years and older
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03487276
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
IFX-1, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Birmingham, Alabama • Fort Myers, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 9, 2026, 10:30 PM EST
Terminated Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04611152
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
48
States / cities
La Jolla, California • Redlands, California • Santa Maria, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 3 Interventional Results available

Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension

NCT01963208
View directory record Official record
Conditions
Drug Resistant Partial Onset Seizure
Interventions
ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 3 Interventional

Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

NCT04549116
View directory record Official record
Conditions
Infertility
Interventions
Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator, Placebo Vaginal gel with applicator, Placebo injectable solution
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
35 Years to 42 Years · Female only
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Tempe, Arizona • Encino, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers

NCT01756404
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Nov 9, 2026, 10:30 PM EST
Terminated Phase 1Phase 2 Interventional Results available

A Study to Assess ASP0598 Otic Solution Following Topical Application in the Ear in Subjects With Chronic Tympanic Membrane Perforation (CTMP)

NCT04305184
View directory record Official record
Conditions
Chronic Tympanic Membrane Perforation
Interventions
ASP0598, Placebo
Drug · Other
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Palo Alto, California • Torrance, California • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Nov 9, 2026, 10:30 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Early Childhood Obesity, Part 1: Family Spirit Nurture, 3-9 Months

NCT03101943
View directory record Official record
Conditions
Obesity, Water; Lack of, Breast Feeding, Tooth Erosion, Dental Plaque, Infant Obesity, Feeding Behavior, Mother-Child Relations, Dietary Habits, Dental Caries
Interventions
Family Spirit Nurture (FSN), Control Program, Water Delivery
Behavioral · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
13 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Shiprock, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 1 Interventional

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

NCT00774943
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
AMG 557
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
11
States / cities
Anniston, Alabama • Phoenix, Arizona • San Leandro, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Nov 9, 2026, 10:30 PM EST
Terminated Phase 2 Interventional Results available

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

NCT01151215
View directory record Official record
Conditions
Neoplasms, Breast Neoplasms, Breast Cancer
Interventions
AZD8931, anastrozole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2014 · Synced Nov 9, 2026, 10:30 PM EST
Recruiting Not applicable Interventional

The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study

NCT07142304
View directory record Official record
Conditions
Chemotherapy Induced Peripheral Neuropathy (CIPN)
Interventions
The Lilac Device, Sham device
Device
Lead sponsor
Luminate Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Poway, California • Norwich, Connecticut • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 3 Interventional Results available

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

NCT01205438
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease
Interventions
LY2127399, Placebo every 2 weeks, Placebo every 4 weeks
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
88
States / cities
Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Nov 9, 2026, 10:30 PM EST
Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 1 Interventional

A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

NCT03625778
View directory record Official record
Conditions
Obesity
Interventions
MEDI0382, Placebo
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Nov 9, 2026, 10:30 PM EST
Recruiting Phase 2 Interventional

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

NCT05538208
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 20 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

NCT04175925
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, BMS-986322 Placebo, famotidine
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 4 Interventional Results available

Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

NCT01006889
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Exenatide
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers

Social Anxiety MDMA-Assisted Therapy Investigation

NCT05138068
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
MDMA, Psychotherapy
Drug · Behavioral
Lead sponsor
Jason B Luoma
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

NCT01579916
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Influenza Virus Vaccine, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Miami, Florida • Stockbridge, Georgia • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

NCT02614547
View directory record Official record
Conditions
Severe Postpartum Depression
Interventions
SAGE-547, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Atlanta, Georgia • Worcester, Massachusetts • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

NCT00831506
View directory record Official record
Conditions
Alzheimer Disease, Huntington Disease
Interventions
digoxin, dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Nov 9, 2026, 10:30 PM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

NCT03912233
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121, TEZ, VX-561, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Los Angeles, California • Oakland, California • Lexington, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Nov 9, 2026, 10:30 PM EST